Nephrology

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

Conditions:   Anemia;   Renal Insufficiency, Chronic
Intervention:   Drug: Mircera
Sponsor:   Hoffmann-La Roche
Not yet recruiting
ClinicalTrials.gov: Nephrology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 12, 2018 / by / in
Cook Enforcer Post-Market Study

Condition:   End-Stage Renal Disease
Interventions:   Device: Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter;   Device: Conventional angioplasty balloon catheters
Sponsor:   Cook Research Incorporated
Not yet recruiting
ClinicalTrials.gov: Nephrology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 11, 2018 / by / in
A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

Condition:   Primary Focal Segmental Glomerulosclerosis
Intervention:   Drug: CXA-10
Sponsors:   Complexa, Inc.;   NephCure Accelerating Cures Institute;   Medpace, Inc.;   MicroConstants;   Arkana Labs;   NephCure Kidney International
Not yet recruiting
ClinicalTrials.gov: Nephrology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

April 7, 2018 / by / in
A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn’s Disease

Conditions:   Ulcerative Colitis;   Crohn’s Disease
Intervention:   Drug: Etrolizumab
Sponsor:   Hoffmann-La Roche
Recruiting
ClinicalTrials.gov: Nephrology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

March 27, 2018 / by / in